A dry consumable preparation and related methods are disclosed. The preparation has a bulking agent, and a cannabinoid and/or a cannabinoid extract containing one or more cannabinoids plated onto the bulking agent. The preparation also has an effervescence agent. The effervescence agent has sodium bicarbonate, potassium bicarbonate, and at least one acid, the at least one acid having at least one of citric acid, tartaric acid, or malic acid. The effervescence agent further has a ratio of sodium bicarbonate to potassium bicarbonate to the acid(s) that creates a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.

Provided are biocompatible topical compositions including a novel combination of an inflammatory management agent, a vascular repair agent, a neurogenic agent, a sebum suppression agent and an exfoliating agent. Also provided are methods for treating, preventing or ameliorating rosacea, a symptom thereof or a condition related thereto by administering the biocompatible topical compositions describe herein.

Provided are biocompatible topical compositions including a novel combination of an inflammatory management agent, a vascular repair agent, a neurogenic agent, a sebum suppression agent and an exfoliating agent. Also provided are methods for treating, preventing or ameliorating rosacea, a symptom thereof or a condition related thereto by administering the biocompatible topical compositions describe herein.

This document provides dietary supplement compositions. For example, multi-supplement compositions having combinations of dietary supplement formulations useful for human or animal consumption are provided.

This document provides dietary supplement compositions. For example, multi-supplement compositions having combinations of dietary supplement formulations useful for human or animal consumption are provided.

The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.

The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.

The instant disclosure relates to nanoparticle compositions that may be used for the targeting of certain cells or tissues. The nanoparticles may take a variety of different forms, including non-viral, viral, and lipid nanoparticles, and may utilize a TNF receptor superfamily member 12A (“TWEAKR”) binding region of the TWEAK protein to target a nanoparticle to tissues expressing TWEAKR. The compositions may further comprise a suicide gene optionally under the control of a tissue specific promoter. In further aspects, methods of treating an individual using the disclosed nanoparticle compositions are described.

The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).